title: Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024.
abstract: OBJECTIVE
  We sought to improve outcomes for patients with high-risk head and neck squamous cell cancer (HNSCC) after surgical resection by testing the feasibility and safety of early postoperative chemotherapy followed by concurrent chemoradiotherapy.
  
  
  METHODS
  Eligible patients had resected, stages III to IV HNSCC with positive margins, extracapsular nodal extension, or multiple positive nodes. Paclitaxel (80 mg/m(2)) was given once weekly during postoperative weeks 2, 3, and 4 and was given before radiation therapy (RT). Paclitaxel (30 mg/m(2)) and cisplatin (20 mg/m(2)) were given once weekly during the last 3 weeks of RT (60 Gy over 6 weeks, beginning 4 to 5 weeks after surgery). The primary end points were treatment safety and tolerability compared with concurrent cisplatin (100 mg/m(2) every 3 weeks) and RT, as tested in Radiation Therapy Oncology Group trial RTOG 9501.
  
  
  RESULTS
  The median follow-up time for the 70 patients enrolled was 3.3 years (range, 0.6 to 4.4 years) for surviving patients. Tolerability of all treatment components was comparable to that of RTOG 9501 treatment, which is the current standard of care (compliance rate, 75%; 95% CI, 63% to 85%). One patient died, and seven patients experienced grade 4 nonhematologic toxicities. Rates of locoregional control, disease-free survival, and overall survival exceeded those of RTOG 9501 after adjustment for important prognostic variables (ie, positive margins, extracapsular extension, primary site, and performance status).
  
  
  CONCLUSIONS
  Chemotherapy soon after surgery followed by concurrent chemoradiotherapy therapy was feasible; tolerance was in line with standard postoperative chemoradiotherapy; and this regimen led to excellent rates of locoregional control and disease-free survival.
authors.affiliation: Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. dirosenthal@mdanderson.org
authors.forename: David I
authors.initials: DI
authors.lastname: Rosenthal
authors.forename: Jonathan
authors.initials: J
authors.lastname: Harris
authors.forename: Arlene A
authors.initials: AA
authors.lastname: Forastiere
authors.forename: Randal S
authors.initials: RS
authors.lastname: Weber
authors.forename: John A
authors.initials: JA
authors.lastname: Ridge
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Myers
authors.forename: Adam S
authors.initials: AS
authors.lastname: Garden
authors.forename: Michael R
authors.initials: MR
authors.lastname: Kuettel
authors.forename: Kulbir
authors.initials: K
authors.lastname: Sidhu
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Schultz
authors.forename: Andy
authors.initials: A
authors.lastname: Trotti
authors.forename: K Kian
authors.initials: KK
authors.lastname: Ang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000601:surgery / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000601:surgery / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods*; D012871:Skin Diseases / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D002945:Cisplatin